These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1640729)

  • 41. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
    Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
    Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
    Wu GQ
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia.
    Simonsson B; Burnett AK; Prentice HG; Hann IH; Brenner MK; Gibson B; Grob JP; Lönnerholm G; Morrison A; Smedmyr B
    Leukemia; 1989 Sep; 3(9):631-6. PubMed ID: 2668654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
    Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O
    Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Autologous bone marrow transplantation in children with acute leukemia or non-Hodgkin's lymphoma].
    Emminger W; Hinterberger W; Emminger-Schmidmeier W; Peters C; Fink FM; Zoubek A; Haas OA; Höcker P; Hawliczek R; Knapp W
    Wien Med Wochenschr; 1991; 141(9-10):225-8. PubMed ID: 1683071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno- and chemotherapy (PTIC).
    Houtenbos I; Bracho F; Davenport V; Slack R; van de Ven C; Suen Y; Killen R; Shen V; Cairo MS
    Bone Marrow Transplant; 2001 Jan; 27(2):145-53. PubMed ID: 11281383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Autologous bone marrow transplantation in pediatric cancer].
    Ohira M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2299-306. PubMed ID: 2260867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
    Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical research on the treatment of acute leukemia with autologous bone marrow transplantation].
    Zheng HJ; Su Y; Zhao YH
    Zhonghua Nei Ke Za Zhi; 1994 Dec; 33(12):824-6. PubMed ID: 7768141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.
    Margolin KA; Van Besien K; Wright C; Niland J; Champlin R; Fung HC; Kashyap A; Molina A; Nademanee AP; O'Donnell MR; Parker P; Smith E; Spielberger R; Somlo G; Snyder D; Stein A; Woo D; Thomas M; Sniecinski I; Forman SJ
    Biol Blood Marrow Transplant; 1999; 5(1):36-45. PubMed ID: 10232739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia.
    Bergmann L; Heil G; Kolbe K; Lengfelder E; Puzicha E; Martin H; Lohmeyer J; Mitrou PS; Hoelzer D
    Leuk Lymphoma; 1995 Jan; 16(3-4):271-9. PubMed ID: 7719235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
    Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
    Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
    Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
    Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL-2 for the treatment of acute leukemias.
    Meloni G; Foa R; Capria S; Tosti S; Vignetti M; Gavosto F; Mandelli F
    Leukemia; 1992; 6 Suppl 2():28-30. PubMed ID: 1578937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.